Study guide
6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin
Medical Council of Canada Qualifying Examination Part I MCCQE Part I
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice
1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics
2 Chapter 2: Population Health, Health Promotion & Preventive Care
2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada
3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems
3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions
4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology
4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers
5 Chapter 5: General Surgery, Orthopedics, & Emergency Care
5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition
6 Chapter 6: Pediatrics & Adolescent Health
6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management
7 Chapter 7: Obstetrics & Gynecology
7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation
8 Chapter 8: Psychiatry & Mental Health
8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)
9 Chapter 9: Neurology, Rheumatology, & Dermatology
9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine
10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice
10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety
6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin
Key Takeaways Explain This Topic AI
Neonatal fever (age ≤ 28 days with temperature ≥ 38.0°C) is a medical emergency requiring full septic workup (blood, urine via catheter, lumbar puncture) and immediate IV empiric antibiotics (Ampicillin + Cefotaxime or Gentamicin).
Classic pediatric exanthems are distinguished by key clinical features: Measles (Koplik spots, maculopapular rash starting at hairline spreading cephalocaudally), Scarlet fever (sandpaper rash, strawberry tongue, Pastia lines), Varicella (dewdrops on a rose petal in various stages of healing).
Kawasaki Disease is diagnosed clinically by fever ≥ 5 days plus 4/5 criteria (conjunctivitis, mucositis/strawberry tongue, rash, cervical lymphadenopathy, extremity changes); immediate IVIG (2 g/kg) and high-dose aspirin are required to prevent coronary artery aneurysms.
Acute Otitis Media (AOM) first-line treatment in Canada is high-dose Amoxicillin (80-90 mg/kg/day); watchful waiting for 48-72 hours is appropriate only for mild cases in children ≥ 6 months with reliable follow-up.
Erythema Infectiosum (Fifth Disease / Parvovirus B19) presents with a "slapped cheek" rash followed by a reticulated lace-like trunk rash; it poses a grave risk of aplastic crisis in sickle cell patients and hydrops fetalis in pregnant women.
Last updated: July 2026
6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin
Evaluating fever and cutaneous eruptions in pediatric patients requires distinguishing benign self-limited viral exanthems from life-threatening systemic bacterial infections and vasculitides. Risk-stratified management of febrile infants and early recognition of Kawasaki disease are heavily tested MCCQE Part I domains.
Management of the Febrile Young Infant (0–90 Days)
Fever in infants is defined as a rectal temperature ≥ 38.0°C (100.4°F) .
Neonatal Age 0 to 28 Days (High Risk)
Neonates possess immature immune systems and are at elevated risk for Invasive Bacterial Infections (IBI: bacteremia, meningitis, urinary tract infection).
Pathogens: Group B Streptococcus (GBS), Escherichia coli (and other Gram-negative bacilli), Listeria monocytogenes , Herpes Simplex Virus (HSV).
Mandatory Full Septic Workup:
Complete blood count (CBC), differential, blood cultures.
Catheterized urinalysis and urine culture.
Lumbar Puncture (LP): CSF cell count, protein, glucose, Gram stain, bacterial culture, HSV PCR.
Inflammatory markers: C-reactive protein (CRP) and Procalcitonin (PCT).
Empiric Treatment: Immediate hospital admission and IV Ampicillin + Cefotaxime (or Ampicillin + Gentamicin). Add IV Acyclovir if HSV features present (maternal history, mucocutaneous vesicles, elevated transaminases, seizures).
Infants Aged 29 to 60 Days
Stratified using validated clinical decision rules (e.g., PECARN, Step-by-Step, or Aronson rules ).
Low-risk infants (reassuring labs, negative urinalysis, low procalcitonin) may undergo selective outpatient management with close 24-hour follow-up. High-risk infants require LP, hospital admission, and IV Ceftriaxone.
Pediatric Viral & Bacterial Exanthems
Disease Pathogen Classic Clinical Features Rash Description Key Complications / Management
Measles (Rubeola) Paramyxovirus 3 Cs: Cough, Coryza, Conjunctivitis + Koplik spots (buccal mucosa) Maculopapular, begins at hairline/face and spreads cephalocaudally Subacute Sclerosing Panencephalitis (SSPE), pneumonia. Vitamin A therapy
Rubella (German Measles) Rubella virus Suboccipital & postauricular lymphadenopathy , Forchheimer spots Erythematous maculopapular rash spreading face down; milder than measles Congenital Rubella Syndrome (cataracts, PDA, sensorineural deafness)
Erythema Infectiosum (Fifth Disease) Parvovirus B19 Low-grade fever, prodrome "Slapped cheek" facial erythema → reticulated lace-like trunk/extremity rash Aplastic crisis in Sickle Cell/spherocytosis; Hydrops fetalis in pregnancy
Roseola Infantum (Exanthem Subitum) HHV-6 (or HHV-7) High fever (39-40°C) for 3-5 days that abates abruptly Maculopapular rash appears AFTER fever breaks , starting on trunk Leading cause of Febrile Seizures in infants aged 6-24 months
Varicella (Chickenpox) Varicella-Zoster Virus (VZV) Pruritic prodrome, fever "Dewdrops on a rose petal" (vesicles on erythematous base) in all stages Secondary bacterial skin infection ( S. pyogenes necrotizing fasciitis), encephalitis
Hand-Foot-Mouth Disease Coxsackievirus A16 / EV71 Fever, painful oral stomatitis Erythematous macules/vesicles on palms, soles, buttocks Dehydration secondary to painful oral ulcers; self-limiting
Scarlet Fever Streptococcus pyogenes (GAS) Fever, exudative pharyngitis, Strawberry tongue Sandpaper-texture rash, accentuation in flexural creases ( Pastia lines ) Post-streptococcal glomerulonephritis, Acute Rheumatic Fever. Tx: Amoxicillin
Kawasaki Disease (Mucocutaneous Lymph Node Syndrome)
Kawasaki disease is an acute self-limiting medium-vessel necrotizing vasculitis with a predilection for coronary arteries. It is the leading cause of acquired heart disease in children in developed countries.
Diagnostic Criteria
Fever lasting ≥ 5 days plus at least 4 of the 5 following clinical features (Mnemonic: CRASH and Burn [Fever]):
C onjunctivitis: Bilateral non-exudative bulbar conjunctival injection.
R ash: Polymorphous non-vesicular exanthem (maculopapular, scarlatiniform, or erythema multiforme-like).
A denopathy: Cervical lymphadenopathy (usually > 1.5 cm diameter, unilateral).
S trawberries: Oral mucosal changes (red cracked lips, strawberry tongue , diffuse pharyngeal erythema).
H ands & Feet: Extremity changes (acute erythema and edema of palms/soles; subungual desquamation in convalescent phase).
Incomplete Kawasaki Disease
Children with unexplained fever ≥ 5 days and 2 or 3 criteria with elevated inflammatory markers (CRP ≥ 30 mg/L, ESR ≥ 40 mm/h) warrant baseline Echocardiography to evaluate for coronary aneurysms.
Management Protocol (CPS Guidelines)
Intravenous Immunoglobulin (IVIG): Single infusion of 2 g/kg administered over 10–12 hours within the first 10 days of fever onset. Significantly reduces coronary artery aneurysm risk from 25% down to < 4%.
Acetylsalicylic Acid (ASA / Aspirin):
High-dose ASA (80–100 mg/kg/day divided q6h) during acute febrile phase.
Transition to low-dose ASA (3–5 mg/kg/day) once afebrile for 48 hours, continued for 6–8 weeks (or indefinitely if coronary aneurysms persist).
Exam Trap: Kawasaki disease is one of the very few pediatric indications for Aspirin despite Reye syndrome risk. Ensure VZV and influenza vaccinations are up to date in children on long-term ASA therapy.
- Common Pediatric ENT Infections
- Acute Otitis Media (AOM)
Diagnosis: Requires acute onset, middle ear effusion (bulging tympanic membrane, loss of landmarks), AND signs of middle ear inflammation (intense erythema, otalgia).
First-Line Antibiotic Therapy (Canada): High-dose Amoxicillin (80–90 mg/kg/day divided BID) for 10 days (<2 years) or 5 days (≥2 years).
Watchful Waiting Option: CPS guidelines allow observation for 48–72 hours WITHOUT initial antibiotics only if: Age ≥ 6 months, mild otalgia, temperature < 39.0°C, non-severe presentation, AND reliable caregiver follow-up guaranteed.
Group A Streptococcal (GAS) Pharyngitis
Diagnosis: Exudative pharyngitis in children > 3 years. Confirm with Rapid Antigen Detection Test (RADT) or throat swab culture.
Treatment: First-line is Oral Penicillin V or Amoxicillin for 10 days. Primary objective is preventing Acute Rheumatic Fever .